ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. The company specialises in high quality medicines for the treatment of important diseases in the livestock sector. ECO Animal Health are dedicated to the research, development and marketing of strong brands, differentiated generics and innovative new solutions.

27 Feb 2026

ECOVAXXIN® MS commercialisation begins

Following the announcement in December 2025 of European Commission marketing authorisation, Eco Animal Health has announced its commercialisation roadmap for deployment of ECOVAXXIN^® MS across key European territories in 2026/27.

The Group notes that it expects sales of ECOVAXXIN^® MS to be immediately margin accretive and, from FY28, make a “material contribution to EBITDA”. In line with Group estimates, we expect peak ECOVAXXIN^®MS revenue of c.£22m¹ by 2031. ECO has outlined a clear path towards commercial contribution from ECOVAXXIN® MS - the first in a pipeline of nine major new products under development. Consequently, we are now comfortable in extending our outlook to FY28E. Our Fair Value increases to 153p/share.

Download as a PDF file

Return to ECO Animal Health

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 3rd Floor, 80 Cheapside, London, EC2V 6EE

Website design & development by Breckenridge